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Abstract
Introduction Dental plaque biofilms are colonized by respiratory
pathogens in mechanically-ventilated intensive care unit
patients. Thus, improvements in oral hygiene in these patients
may prevent ventilator-associated pneumonia. The goal of this
study was to determine the minimum frequency (once or twice a
day) for 0.12% chlorhexidine gluconate application necessary to
reduce oral colonization by pathogens in 175 intubated patients
in a trauma intensive care unit.
Methods A randomized, double-blind, placebo-controlled
clinical trial tested oral topical 0.12% chlorhexidine gluconate or
placebo (vehicle alone), applied once or twice a day by staff
nurses. Quantitation of colonization of the oral cavity by
respiratory pathogens (teeth/denture/buccal mucosa) was
measured.
Results Subjects were recruited from 1 March, 2004 until 30
November, 2007. While 175 subjects were randomized,
microbiologic baseline data was available for 146 subjects, with
115 subjects having full outcome assessment after at least 48
hours. Chlorhexidine reduced the number of Staphylococcus
aureus, but not the total number of enterics, Pseudomonas or
Acinetobacter in the dental plaque of test subjects. A non-
significant reduction in pneumonia rate was noted in groups
treated with chlorhexidine compared with the placebo group
(OR = 0.54, 95% CI: 0.23 to 1.25, P = 0.15). No evidence for
resistance to chlorhexidine was noted, and no adverse events
were observed. No differences were noted in microbiologic or
clinical outcomes between treatment arms.
Conclusions While decontamination of the oral cavity with
chlorhexidine did not reduce the total number of potential
respiratory pathogens, it did reduce the number of S. aureus in
dental plaque of trauma intensive care patients.
Trial Registration clinicaltrials.gov NCT00123123.
ANOVA: analysis of variance; APACHE: Acute Physiology and Chronic Health Evaluation; BqBAL: blind quantitative bronchoalveolar lavage; cfu: col-
ony forming units; CHX: chlorhexidine gluconate; CI: confidence interval; CPIS: clinical pulmonary infection score; ECMC: Erie County Medical 
Center; FiO2: fraction of inspired oxygen; HR: hazards ratio; MV-ICU: mechanically ventilated, intensive care unit; OR: odds ratio; PaO2: partial pres-
sure of arterial oxygen; PRPs: potential respiratory bacterial pathogens; SID: subject Identification Numbers; VAP: ventilator-associated pneumonia.Critical Care    Vol 13 No 4    Scannapieco et al.
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Introduction
The pathogenesis of ventilator-associated pneumonia (VAP)
involves aspiration of bacteria from the oropharynx into the
lung, and subsequent failure of host defenses to clear the bac-
teria resulting in development of lung infection [1]. In mechan-
ically ventilated, intensive care unit (MV-ICU) patients, the
major potential respiratory bacterial pathogens (PRPs) include
Staphylococcus aureus, Pseudomonas aeruginosa, Acineto-
bacter species, and enteric species. Previous studies have
shown that dental plaque and the oral mucosa are often colo-
nized by PRPs [2,3]. Also, PRPs from dental plaque of MV-ICU
patients are genetically identical to strains from broncho-
scopic cultures taken at the time pneumonia was suspected,
[4,5]. These findings suggest that dental plaque may be an
important reservoir of PRPs that cause VAP. Thus, improving
oral hygiene in MV-ICU patients and reducing dental plaque
load on teeth has the potential to reduce the risk of VAP.
Topical oral application of antiseptics such as chlorhexidine
gluconate (CHX) have been evaluated for the prevention of
VAP. CHX is a cationic chlorophenyl bis-biguanide antiseptic
that has long been approved for use as an inhibitor of dental
plaque formation and gingivitis [6-8]. CHX is of particular inter-
est as an oral disinfectant in MV-ICU patients because of its
substantivity (the ability of CHX to bind to oral tissues with
subsequent slow release and thus a relatively long period of
action). Several recently published clinical trials of intra-oral
disinfection with topical CHX [9-15] or povidone-iodine gargle
and tooth-brushing [16] have demonstrated a reduction in the
prevalence of oropharyngeal colonization by PRPs, as well as
a reduction in the rate of VAP in MV-ICU patients. Based on
these observations, recommendations for preventing VAP
have included improving oral hygiene in MV-ICU patients
[17,18]. However, not all studies of the use of CHX have
shown a reduction in the incidence of pneumonia [19]. More-
over, the studies that have been published used different CHX
dosing regimes and did not always clearly define the method
of application of CHX. Identification of the minimum frequency
for CHX application required to reduce the number of PRPs
on the teeth may promote the routine use of this intervention
for MV-ICU patients. However, the most simple method for
application and the minimally effective dosing regime of CHX
that improves oral hygiene to reduce the number of PRPs in
dental plaque biofilms has not been determined.
Thus, the goal of the present study was to determine the min-
imal frequency of oral CHX application (once or twice a day),
compared with placebo, which significantly reduces oral colo-
nization by PRPs in MV-ICU patients. Secondary endpoints
included incident VAP, duration of mechanical ventilation,
length of ICU stay, and rate of mortality.
Materials and methods
Patient population
This trial was approved by the University at Buffalo Institutional
Review Board. Subjects for this study were recruited from
patients admitted to the 18-bed trauma ICU of the Erie County
Medical Center (ECMC) who were mechanically ventilated.
ECMC is a 550-bed inpatient level 1 regional center for
trauma, burn care, and rehabilitation and is an affiliated teach-
ing facility for the State University of New York at Buffalo. This
ICU is 'closed', in that all patients who are admitted are prima-
rily managed by the study intensivist physician (KR) or his sur-
rogates. The average length of stay in this unit in the year
before the start of the study was approximately six days. Over
the past five years the incidence of VAP has ranged from 10
to 50% of all MV patients, and VAP per 1000 ventilator days
has ranged from 8 to 12. Once participant eligibility was
established, written informed consent was obtained from each
patient, or most often from his/her next of kin or health care
proxy.
Sample size estimate
Based on previous studies, it was conservatively estimated
that approximately 50% of all subjects admitted to the ICU
would be colonized by a PRP. In order to have a 90% power
of detecting a difference between colonization proportions,
and assuming a dose-response effect whereby 50% of the
placebo group would be presumed to be colonized, with 25%
of the twice daily CHX group, and 20% of the once daily CHX
group, it was determined that a minimum group size would
require 53 participants per treatment arm.
Inclusion/exclusion criteria
Eligible patients were those admitted to the ICU who were
expected to be intubated and mechanically ventilated within
48 hours of admission, with the exception of those demon-
strating the following exclusion criteria: a witnessed aspiration
(to eliminate patients with chemical pneumonitis); a confirmed
diagnosis of post-obstructive pneumonia (e.g. advanced lung
cancer); a known hypersensitivity to CHX; absence of con-
sent; a diagnosed thrombocytopenia (platelet count less than
40 and/or a INR above 2, or other coagulopathy); a do not intu-
bate order; children under the age of 18 years; pregnant
women; legal incarceration; transfer from another ICU; oral
mucositis; immunosuppression (either-HIV or drug induced
(e.g. organ transplant patients or those on long term steroid
therapy)); and re-admission to the ICU.
Trial design
Eligible patients, after giving informed consent and following
baseline assessment, were randomly assigned to one of three
arms (Figure 1): 1) a control arm in which patients received
twice daily oral topical applications (AM and PM) with the
CHX vehicle control alone (having the same color, taste, and
smell as the CHX rinse); 2) an experimental arm in which
patients received once daily oral topical treatment with 0.12%Available online http://ccforum.com/content/13/4/R117
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CHX and once daily oral topical treatment with vehicle control
(subjects were randomly selected to receive CHX in the morn-
ing and placebo in the evening, or CHX in the evening and pla-
cebo in the morning); and 3) an additional experimental arm in
which patients received twice daily oral topical treatments with
0.12% CHX gluconate.
CHX formulation
The oral rinse was formulated [20] as follows: 3 ml chlorhexi-
dine gluconate 20% added to 200 ml of distilled water; sepa-
rately 5 ml essence of peppermint was mixed with 5 ml 95%
ethanol, and then 15 ml glycerin. The solutions were then
mixed and brought to 500 ml with distilled water. The placebo
contained all ingredients, except for CHX, which was substi-
tuted with distilled water.
Concealment, blocking, and randomization
Subjects were randomized to the study via a web-based sub-
ject enrollment system that used protocol-specific specifica-
tion files that presented questions to site personnel to evaluate
eligibility. Only subjects who met all eligibility requirements
were randomized to the study. The randomization system pre-
pared a set of Subject Identification Numbers (SID) that iden-
tified individual treatment assignments. The study nurse
obtained the SID number based on the randomization when
the subject was enrolled. The assigned SID number was sent
to the study pharmacist to dispense the appropriate blinded
treatment. Assignment of treatment was blinded to patients
and all investigators including outcome assessors, statisti-
cians, and care providers. Sealed envelopes containing a ran-
dom number were generated in blocks of six to provide
Figure 1
Study design Study design. The final analysis was based on subjects having a microbiologic assessment at baseline and for at least the 48 hour (h) time point (n 
= 42 in the placebo group, 36 in the chlorhexidine gluconate (CHX) once a day group, and 37 in the CHX twice a day group).Critical Care    Vol 13 No 4    Scannapieco et al.
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concealment of patient assignment from the investigators.
Each block of six numbers were assigned corresponding
boxes prepared and numbered sequentially from one to six.
The pharmacists prepared each box to contain two 32 oz bot-
tles, one labeled AM and one labeled PM. For each block one
of 720 possible permutations of symbols (Placebo 1(P1), Pla-
cebo 2 (P2), Once AM 1 (OM1), Once PM 1 (OM2), Twice a
day 1 (T1), Twice a day 2 (T1)) were selected using a random
number generator, and numbers one to six were assigned
based on randomly selected permutations. The oral topical
treatment for each box was formulated and prepared by the
hospital pharmacy.
Intervention
CHX was applied using a rinse-saturated oral foam applicator
(Sage Products, Cary, IL, USA) twice each day (in the morning
at about 8 AM and in the evening at about 8 PM). Applications
were for one minute with about 1 oz of 0.12% CHX or pla-
cebo. The ICU staff nurses performed CHX application. All
teeth, the oral soft tissues including buccal mucosa, vestibule,
gingiva, and the floor of the mouth and tongue dorsum were
swabbed. Excess rinse was suctioned out of the subject's
mouth after one minute. In addition to this rinse, the routine oral
care regime used by the ICU was maintained throughout the
course of the trial. Briefly, routine oral care included use of a
suction toothbrush (Sage Products, Cary, IL, USA) twice a day
and as needed to brush teeth and the surface of the tongue,
for approximately one to two minutes, and applying suction at
completion and as needed during the brushing. In addition,
swabbing with Peroxamint solution (Sage Products, Cary, IL,
USA) was performed every four hours. This was followed by
the application of a mouth moisturizer (Sage Products, Cary,
IL, USA) to the oral mucosa using a fresh swab. Also, deep
suctioning was performed to assist in removing oropharyngeal
secretions pooled on top of the cuff of the endotracheal tube
every 12 hours and following position changes.
The study nurses trained all ICU staff nurses to perform the
standardized technique for application of the rinse. The study
nurses periodically observed ICU staff nurses for adherence to
study protocol. Routine in-service sessions were held every
three months to review the protocol with ICU staff nurses. The
study nurses collected all samples and study data and fol-
lowed each enrolled subject until they were exited from the
study.
Dental plaque and airway sampling
Dental plaque samples were collected on the day of admission
to the ICU (baseline sampling) and every 48 hours thereafter
until discharge from the study. Samples consisted of suprag-
ingival dental plaque pooled from at least two remaining teeth,
or if the patient was edentulous, from the buccal mucosa, or, if
they were wearing a denture, from the tissue surface of the
maxillary denture. Samples were collected with a sterile stain-
less steel curette and dispersed into 2 ml of sterile normal
saline. For patients who were edentulous and not wearing
dentures, the buccal mucosa was sampled by vigorous rub-
bing with a sterile swab and dispersed into sterile normal
saline (2 ml). Sampling was performed prior to routine daily
oral care. Samples were immediately sent to the laboratory for
processing.
Tracheal samples were obtained from all intubated patients at
each sampling interval (baseline and every 48 hours) using a
sterile suction catheter placed into the endotracheal tube.
When pneumonia was suspected (see below), lung secretions
were obtained and analyzed for bacterial infection by Blind
Quantitative Bronchoalveolar Lavage (bqBAL) using a mini-
BAL technique.
Microbiological procedures
Samples were vortexed for one minute and split into 4 to 0.5
ml portions (with three of the samples placed at -70°C). The
remaining dental plaque samples were diluted and plated
using a spiral plater on sheep's blood agar (to isolate S.
aureus), and MacConkey agar (for isolation of Gram-negative
bacilli). For tracheal secretions, semi-quantitation of PRPs was
performed (0 to 4+ range scored). Microbial cultures were
incubated for 72 hours at 37°C in 5% carbon dioxide. Plates
were assessed for growth of the following target PRPs: S.
aureus, P. aeruginosa, Acinetobacter species, and enteric
organisms (Klebsiella pneumoniae,  Serratia marcescens,
Enterobacter  species,  Proteus mirabilis,  Escherichia coli).
Results of quantitative cultures were expressed as colony
forming units (cfu) per ml. A bqBAL sample was considered
positive if 104 CFU/ml or more of a PRP was found.
For measurement of CHX resistance, dental plaque and lower
airway secretions processed for microbiologic analysis as
described above, were plated on trypticase soy agar with and
without a final concentration of 0.12% CHX gluconate. Plates
were incubated both aerobically and anaerobically for 72
hours and the proportion of CHX-resistant colonies enumer-
ated.
Patient data, outcome variables, and potential 
confounding variables
All subjects entered into the study were followed for up to 21
days, or on discharge from the ICU, extubation, or death.
Although it was uncertain when planning the trial that enough
subjects could be recruited to discern a statistically significant
effect of the oral intervention on incident VAP, we selected as
primary outcome variables dental plaque score and coloniza-
tion of the oral cavity by respiratory pathogens (S. aureus, P.
aeruginosa, Acinetobacter species, and the enteric species K.
pneumoniae, S. marcescens, Escherichia species, P. mirabi-
lis, and E. coli) by quantitative culture measured at baseline
and subsequently at 48-hour intervals until the subject was
discharged from the ICU.Available online http://ccforum.com/content/13/4/R117
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Secondary outcomes assessed were: diagnosis of pneumonia
in a MV patient at least 48 hours following admission to the
ICU (see below); mortality following admission and during the
stay in the ICU; length of ventilation in the ICU; and length of
stay in the ICU.
The clinical pulmonary infection score system (CPIS) used is
based on five different elements: partial pressure of arterial
oxygen (PaO2)/fraction of inspired oxygen (FiO2); Infiltrate on
chest radiograph; Leukocytosis; purulent secretions; and
fever. The CPIS score was calculated as follows: 1) Fever: 0
(36.5 to 38.4°C), 1 (38.5 to 39), 2 (<36.0 OR >39.0); 2) Leu-
kocytosis: 0 (4000 to 11,000 wh.ite blood cells per mm3 of
blood), 1 (11,000 to 17,000), 2 (>17,000); 3) New infiltrate:
0 = None, 1 = Patchy, 2 = Localized; 4) Secretions: 0 = None
to minimal, 1 = moderate, 2 = large amount; and 5) PaO2/
FiO2: 0 = more than 330 and 2 = less than 330.
A CPIS score 6 or more triggered sampling of the lower airway
by bqBAL using a Combicath® (KOL Bio Medical Instruments,
Chantilly, VA, USA). Briefly, this technique involves insertion of
the Combicath through the endotracheal tube and its
advancement until resistance was encountered [21,22]. The
catheter was then withdrawn by a cm, the inner portion of the
co-axial catheter advanced to dislodge the poly-ethylene gly-
col plug, and then 50 ml of normal saline was instilled through
the catheter. After 30 seconds, the specimen was withdrawn
and sent for quantitative bacteriology. The presence of 104
cfu/ml or more of a target PRP in bqBAL fluid or a positive
pleural fluid culture in the absence of previous pleural instru-
mentation was considered as positive evidence for a diagnosis
of pneumonia.
The following demographic information was recorded: age;
gender; race; admission diagnosis; admitted from i) commu-
nity, ii) hospital ward, iii) other ICU, or iv) nursing home.
The following variables were assessed following patient dis-
charge: total days of hospital admission; type of antibiotic ther-
apy (within 14 days), and total duration in days prior to
admission to the ICU.
The severity of illness score utilizing the Acute Physiology and
Chronic Health Evaluation (APACHE) II system was deter-
mined for each subject at baseline [23]. This index utilizes
information obtainable from the patient's hospital record,
including physiologic information (temperature, mean arterial
pressure, heart prevalence, respiratory prevalence, oxygena-
tion, arterial pH, serum levels of Na, K and creatinine, hemat-
ocrit, white blood count), and age.
Oral examination
The study nurse performed a baseline oral examination. Fol-
low-up oral examination and clinical sample collection was
performed every 48 hours until the patient was discharged
from the study. The oral examination consisted of a simplified
plaque index and the enumeration of missing teeth. The plaque
index was performed for six teeth (the upper right first molar,
upper right central incisor, upper left first bicuspid, lower left
first molar, lower left central incisor, and lower right first bicus-
pid). A Michigan O-probe and oral mirror were used to assess
plaque. Only the mesial-buccal and mesial-lingual surfaces at
the gingival margin of the teeth were scored. The amount of
plaque present on the tooth was scored 0 to 3 as follows: 0 =
no plaque noted; 1 = plaque seen only on the tip of an explorer
passed over the tooth surface; 2 = plaque obvious with the
naked eye; 3 = gross deposits of plaque present over the
entire tooth.
The plaque index was calculated as the average of the scores
obtained from the six teeth. For those patients missing any of
the index teeth, or those with endotracheal tube placement
and/or security that precluded examination, teeth available to
be examined closest to the missing teeth were scored. Only a
single score was given for each tooth, representing the sur-
face harboring the most plaque.
The hard-palate, soft palate, buccal mucosa, tongue, and gin-
giva were examined for abnormalities, including inflammation,
ulceration or other signs of inflammatory irritation that might be
expected to be secondary to exposure to CHX.
Adverse events
All subjects were monitored for potential adverse events,
which included intraoral events (mucositis, thrush, tooth stain-
ing, alterations in taste, tooth hypersensitivity) and systemic
adverse events (mortality).
Data management
Once subjects were enrolled to the study site, study personnel
completed protocol specific case report forms according to
the study evaluation schedule. The case report forms were
entered into the study database via a distributed data entry
system.
Computerized data checks were run on the data as it was
entered into the database. These computerized checks were
tracked for resolution. The study data manager also ran manual
QA checks for inconsistent data. Inconsistent data items were
queried by the study data manager, which were followed to
resolution.
Statistical analysis
All tests were carried out using intent-to-treat analysis. All tests
were two-sided using a significance level of 0.05. Baseline
comparisons between groups were performed using analysis
of variance (ANOVA) and/or the chi-squared test, as appropri-
ate. The primary outcome variable, the colonization of the oral
cavity by target respiratory pathogens, was observed in each
patient until their discharge from the ICU. A mixed effect modelCritical Care    Vol 13 No 4    Scannapieco et al.
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was used to compare overall treatment effects between
groups for repeated measures data. It is known that, under the
assumption that data is randomly missed, a likelihood based
method (such as the mixed effect model) provides unbiased
inference regardless of missing data. The group comparison
for each time point was performed using ANOVA. All second-
ary continuous variables with repeated measures data were
analyzed similarly. The group comparisons with categorical
variables were carried out using the chi-squared test. Time to
VAP was defined as the interval between the time of enroll-
ment and time of the first diagnosis of pneumonia, as con-
firmed by a positive bqBAL. Probability plots for time to VAP
were estimated by the Kaplan-Meier method. The distributions
of time to VAP were compared using the Cox proportional haz-
ards model.
Results
Description of study participants
The study design and patient recruitment outcomes are
depicted in Figure 1. Initiation of patient recruitment com-
menced on 1 March, 2004 and ended on 30 November, 2007.
A total of 2409 patients were admitted to the ICU during this
period. Of these, a total of 820 were ventilated and therefore
potentially eligible for inclusion. Patients were admitted to the
study who showed no criteria for exclusion, and who, following
consultation with the attending physician and nursing staff,
would likely remain ventilated for at least 48 hours. Of the 175
patients who initially provided informed consent and who were
randomly assigned to one of three groups (placebo – vehicle
control, CHX once a day, CHX twice a day), 19 were extu-
bated or expired before sampling. Another 10 subjects were
eliminated from the analysis due to missing data, leaving 146
patients having microbiologic data at least at baseline. Thus,
analysis of the primary outcomes (dental plaque score and the
colonization of target pathogens present in dental plaque) was
performed on data from 146 subjects. Of these, 115 were
assessed at 48 hours (e.g. microbiologic assessment at the
48 hour time point (n = 42 in the placebo group, 36 in the
CHX once a day group, and 37 in the CHX twice a day group),
93 subjects were assessed at 96 hours, 74 subjects at 144
hours, 69 at 192 hours, 57 subjects at 240 hours, 40 subjects
at 288 hours, 30 subjects at 336 hours, 38 subjects at 384
hours, 20 subjects at 432 hours, and finally 12 subjects at 480
hours. In addition, intent to treat survival analysis was per-
formed for all 175 patients who were initially randomized.
Demographic and clinical characteristics of the subjects
enrolled in this study are presented in Table 1. The median age
of the 146 study subjects was 48.0 years (range: 18.0 to
87.5), with the majority being white males admitted from the
community. The groups were well balanced with respect to
age, gender, APACHE score at baseline, and antibiotic expo-
sure before inclusion in the study (Table 1). Of the 146 sub-
jects, 16 were edentulous: 7 of 49 in the control group, 3 of
47 in the CHX once a day group, and 6 of 50 in the CHX twice
a day group (P = 0.4449). We found no correlations between
co-morbidities and group assignment (Table 1).
Dental plaque scores and microbiology results
Neither CHX once a day or twice a day showed a significant
reduction in plaque scores when compared with the placebo
group (Figure 2, overall treatment effect P = 0.8423). CHX
delivered once or twice a day yielded similar results with
respect to the number of PRPs in dental plaque samples.
When compared with the placebo control group, no reduction
in total counts or PRPs as a percentage of total cultivable flora
were noted between the placebo and either CHX group, at all
time points (Figure 3, overall treatment effect P = 0.6750). In
addition, the total number of cfus recovered as enterics, Pseu-
domonas and Acinetobacter were not reduced by CHX at any
time point. A statistically significant reduction was, however,
noted in the total number of S. aureus recovered in the CHX
groups when compared with the placebo group (Figure 4, P =
0.0065 and 0.0201 at day 2 and day 4, respectively). CHX
treatment also did not appear to reduce tracheal colonization
by PRPs (data not shown).
Dental plaque samples from the first 100 subjects enrolled
into the study were also plated on blood agar plates supple-
mented to 0.12% CHX. In all cases, these plates showed no
growth, demonstrating that the intervention did not select for
CHX-resistant bacteria.
Clinical pulmonary results
No intra oral adverse events were noted, including mucositis
or tooth staining. No significant differences were found
between groups (Table 1) with respect to antibiotic use, ven-
tilator days, days in the hospital, mean CPIS score (Figure 5),
or mortality. When pneumonia was defined as the presence of
more than 104 cfu of pathogen/ml of bqBAL fluid, among all
175 patients, 12 subjects in the control group were found to
have pneumonia; in the CHX once a day group, 7 subjects
were diagnosed with pneumonia, while in the CHX twice a day
group 7 subjects also had pneumonia. Using intent-to-treat
analysis, a 41% of reduction in the rate of pneumonia was
noted between the treated and placebo group (odds ratio
(OR) = 0.54, 95% confidence interval (CI): 0.23 to 1.25, P =
0.1459); however, the differences were found not to be statis-
tically significant (P = 0.1459). The incidence of pneumonia by
survival analysis showed that the onset of pneumonia tended
to be delayed in the treated groups when compared with the
control group; however, these differences were not statisti-
cally significant (hazards ratio (HR) = 0.555, 95% CI: 0.256 to
1.201, P = 0.1348). If patients who were discharged or diag-
nosed with pneumonia on the day of enrollment into the study
(five and one patients, respectively) were excluded, a
decreased risk for VAP in the CHX-treated group (HR =
0.514, 95% CI: 0.234 to 1.127, P = 0.0966) was observed.Available online http://ccforum.com/content/13/4/R117
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No differences were noted between groups in the number of
missed doses of CHX (or placebo) delivered to each subject
(Table 1).
Discussion
As VAP continues to be a common complication of critical
care, development of preventive approaches are essential to
reduce the incidence of this costly infection. The goal of the
present trial was to determine the minimum frequency (once or
twice a day) of oral decontamination with 0.12 CHX required
to improve oral hygiene and reduce oral colonization by poten-
tial respiratory pathogens in intubated MV patients admitted to
the trauma ICU. The strengths of this trial include the well-con-
trolled, randomized, blinded, well-concealed, and blocked
design, and the fact that the intervention was provided by staff
nurses, thus allowing for the test of the intervention under 'real
world' conditions.
The results show that the use of oral topical CHX resulted in a
quantitative reduction in the number of S. aureus cfus in the
Table 1
Subject characteristics and outcomes between groups
Variables Total
(n = 146)
Control
(n = 49)
CHX*1
(n = 47)
CHX*2
(n = 50)
P value
Age (years) 48.0 ± 20.8 50.0 ± 22.5 44.8 ± 19.9 47.6 ± 19.1 0.3948
Gender – male/female 104/42 36/23 43/15 44/14 0.1570
Race 0.3661
White 117 (88%) 43 (88%) 37 (78%) 37 (74%)
African American 24 (17%) 4 (8%) 10 (22%) 10 (20%)
Asian 2 (1%) 1 (2%) 0 (0%) 1 (2%)
American Indian 3 (1%) 1 (2%) 0 (0%) 2 (4%)
Admitted from 0.0989
Internal hospital ward 6 (4%) 5 (10%) 1 (25) 0 (0%)
External community 116 (80%) 38 (76%) 37 (79%) 41 (82%)
Other 24 (16%) 6 (12%) 9 (19%) 9 (18%)
Co-morbidities 68 (47%)* 24 (50%) 19 (40%) 25 (51%) 0.5212
Cardiac 35 (24%) 13 (27%) 10 (21%) 12 (25%) 0.8039
Pulmonary 16 (11%) 7 (15%) 3 (6%) 6 (12%) 0.4245
Renal 5 (3%) 2 (4%) 0 (0%) 3 (6%) 0.2483
Hepatic 2 (1%) 2 (4%) 0 (0%) 0 (0%) 0.1316
Endocrine 24 (17%) 10 (21%) 6 (13%) 8 (16%) 0.5715
Central nervous 21 (15%) 9 (19%) 8 (17%) 4 (8%) 0.2844
Neoplastic 10 (7%) 4 (8%) 2 (4%) 4 (8%) 0.6764
Immunosuppression 2 (1%) 0 (0%) 0 (0%) 2 (4%) 0.1400
APACHE (baseline) 19.1 ± 5.5 19.1 ± 6.1 18.5 ± 4.1 19.7 ± 6.1 0.5850
Antibiotic exposure before study inclusion 43 (29%) 18 (37%) 12 (26%) 13 (26%) 0.3896
Antibiotic exposure after study inclusion 103 (71%) 32 (65%) 34 (72%) 37 (74%) 0.6043
Antibiotic use 3.5 ± 3.6 3.1 ± 3.5 3.8 ± 3.6 3.7 ± 3.8 0.6057
Days ventilated 9.1 ± 5.6 9.7 ± 6.3 9.4 ± 5.0 8.4 ± 5.2 0.5180
Days in hospital 11.4 ± 6.6 11.3 ± 6.7 12.0 ± 6.3 11.0 ± 6.8 0.7263
Deaths 24 (17%) 8 (17%) 8 (17%) 8 (16%) 0.9834
Missing doses 0.7 ± 1.1 0.9 ± 1.2 0.7 ± 1.3 0.5 ± 0.8 0.2844
*Some patients had multi-comorbidities.
APACHE = Acute Physiology and Chronic Health Evaluation; CHX = chlorhexidine gluconate.Critical Care    Vol 13 No 4    Scannapieco et al.
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dental plaque of MV-ICU patients. The finding that CHX treat-
ment reduced the number of S. aureus in the oral cavity sup-
ports previously published studies that suggest that S. aureus
is vulnerable to CHX disinfection [14]. However, CHX did not
appear to reduce the total number or proportion of other target
PRPs in dental plaque (Pseudomonas, Acinetobacter or
enteric species). Although the group size was not sufficiently
large to show a statistically significant reduction in the inci-
dence of VAP between groups, there was a trend for fewer
cases of VAP in both CHX groups.
There are several possible explanations to explain why CHX
did not reduce the numbers of Gram-negative pathogens in
oral biofilms. First, it is known that Gram-positive pathogens
such as S. aureus are more sensitive to CHX than are Gram-
negative pathogens [13,24]. Second, because dental plaque
biofilm was the primary oral sample analyzed, it is likely that the
Figure 2
Effect of topical CHX on dental plaque scores (mean) and 95% confidence intervals Effect of topical CHX on dental plaque scores (mean) and 95% confidence intervals. Triangle = placebo; Square = chlorhexidine gluconate (CHX) 
once a day; Circle = CHX twice a day. Days represent duration following mechanical ventilation. The confidence intervals were obtained based on 
data at each time point.
Figure 3
Effect of topical chlorhexidine gluconate on the number of potential respiratory bacterial pathogens in oral samples Effect of topical chlorhexidine gluconate on the number of potential respiratory bacterial pathogens in oral samples. Mean in log scale with 95% con-
fidence intervals. The confidence intervals were obtained based on data at each time point. Triangle = placebo; Square = chlorhexidine gluconate 
(CHX) once a day; Circle = CHX twice a day.Available online http://ccforum.com/content/13/4/R117
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organisms cultured from the biofilm were resistant to the topi-
cally delivered antimicrobial agent. It is well known that bacte-
ria that adopt a biofilm lifestyle are usually resistant to
antimicrobial agents. Such resistance has been attributed to
slow growth in the biofilm, the induction of stress responses,
and or production of exopolysaccharides or other extracellular
components that exclude the antimicrobial agent from the bac-
terial community within the biofilm [25].
A number of published studies suggest that topical CHX twice
a day prevents VAP [11-15,26]. Furthermore, several studies
have demonstrated the genetic similarity of bacteria isolated
from the lung to bacteria isolated from dental plaque, demon-
strating that dental biofilms are an important reservoir for these
pathogens [4,5]. Thus, mechanisms other than reduction of
PRPs in dental biofilm must be considered to help explain the
apparent efficacy of this agent to prevent VAP. One possibility
is that CHX inhibits the viability of the planktonic bacteria in the
Figure 4
Effect of topical chlorhexidine gluconate on the number of Staphylococcus aureus in oral samples Effect of topical chlorhexidine gluconate on the number of Staphylococcus aureus in oral samples. Mean in log scale with 95% confidence intervals. 
The confidence intervals were obtained based on data at each time point. Triangle = placebo; Square = chlorhexidine gluconate (CHX) once a day; 
Circle = CHX twice a day.
Figure 5
Effect of CHX on mean clinical pulmonary infection score with 95% confidence intervals Effect of CHX on mean clinical pulmonary infection score with 95% confidence intervals. Triangle = placebo; Square = chlorhexidine gluconate 
(CHX) once a day; Circle = CHX twice a day. The confidence intervals were obtained based on data at each time point.Critical Care    Vol 13 No 4    Scannapieco et al.
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oral secretions. The subsequent reduction in the number of
viable PRPs in the secretions thus reduces the number of via-
ble organisms aspirated into the lower airway and therefore
will prevent subsequent infection. Alternatively, the virulence
potential of the bacteria may be reduced by CHX. Previous
studies have suggested that CHX is able to bind to bacterial
components such as lipopolysaccharide and proteases [27-
29]. Such interactions may diminish the biologic activity of
such components to reduce the virulence potential of bacteria.
It is also possible that concomitant use of other oral care prod-
ucts such as toothpaste might reduce CHX efficacy [30].
Adverse events have rarely been reported in clinical trials of
CHX in ICU patients. A meta-analysis of seven clinical trials
found that adverse effects were not reported in any of these
studies [31]. A recent clinical trial of 2% CHX versus saline
found that 9.8% in the CHX group had mucosal irritation ver-
sus 0.9% in saline controls (P = .001). The present study
using 0.12% CHX found no adverse effects (mucosal irritation
or tooth staining).
No previous published clinical trials of CHX in the context of
VAP have assessed resistance to this agent during the study.
In the present study, an effort was made to identify resistance
to CHX by plating samples of dental plaque or lower airway
secretions on agar containing 0.12% CHX. Although this
approach most likely detects high level CHX resistance, no
such resistant bacterial colonies were noted using this
method. This finding indicates that resistance to CHX was not
likely to be an explanation for the findings of this study.
Previous meta-analyses of trials conclude that this CHX is
effective in prevention of VAP [31,32]. These analyses
revealed, however, that there was variation in the populations
studied as well as in the concentration, preparation, and dos-
ing schedule of CHX. Clinical trials of CHX have tested con-
centrations of 0.12%, 0.2%, and 2%, applied two to four times
a day, and delivered as a rinse, gel or in Vaseline. Thus,
although topical application of CHX to the oral cavity of venti-
lated ICU patients in some cases appears to prevent VAP, the
optimal concentration and frequency of application of this
agent has not been validated. The present study was designed
to determine if there was any difference in oral colonization
with PRPs between once versus twice daily 0.12% CHX.
There was no significant difference between once versus
twice daily 0.12% CHX solution in terms of reducing oral col-
onization by PRPs, with the exception of S. aureus, whose
numbers were reduced in dental plaque of individuals treated
with CHX delivered once or twice a day.
Other environmental factors may also help explain the appar-
ent limitation of CHX to reduce the number of PRPs in the oral
cavity. The nurses at the hospital where the trial was con-
ducted are well educated on the possible role of oral hygiene
in VAP. The standardized oral care regime in place includes
the debridement of the teeth and tongue by use of a suction
toothbrush used twice a day together with swabbing with a
peroxide rinse, swabbing with a peroxide rinse-impregnated
swab every four hours, and use of a mouth moisturizer applied
to the oral mucosa. Deep oropharyngeal suctioning is per-
formed prior to major position changes and extubation, and as
needed to remove oropharyngeal secretions that have pooled
on top of the cuff of the endotracheal tube. This regime may
have already reduced the number of organisms in the dental
plaque to a level where additional reductions by CHX were not
detectable. On the other hand, suctioning excess fluid at the
time of application could have reduced the effect of CHX.
Also, approximately 70% of the subjects enrolled in the
present study were given antibiotics for reasons other than the
development of VAP during the course of their ICU stay, for
example for surgical prophylaxis or for treatment of another
infection. Such exposure to antibiotics might have reduced the
efficacy of CHX in this setting.
In summary, CHX applied topically once or twice a day to the
oral cavity inhibited the numbers of S. aureus in the dental
plaque of MV-ICU patients. An absence of an effect on the
total number of target pathogens, or on Gram-negative spe-
cies, is consistent with previous studies [13]. Perhaps an
increase in the concentration of CHX or in the frequency of
application would be more effective in reduction of pathogenic
bacteria in oral biofilms. Additional large-scale clinical trials are
required to determine the efficacy of CHX in the prevention of
VAP in MV-ICU patients. Alternative approaches to reduce or
eliminate PRPs from the oral cavity should also be studied,
which may include other topical chemotherapeutic agents or
frequent mechanical dislodgment of biofilms from the oral sur-
faces.
Conclusions
The results of this trial show that oral topical CHX reduces the
number of viable S. aureus in the dental plaque of MV-ICU
patients. However, CHX did not reduce the total number or
proportion of other target PRPs (Pseudomonas,  Acineto-
bacter or enteric species) in dental plaque.
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